David King, MD
Hospitalist · Washington, DCNPI 1992746127
Payments from drug & device makers
What this record shows
10 manufacturers reported payments, led by Intuitive Surgical at 47.1% of the total. Among hospitalist clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$226
- AstraZeneca$53
- Pfizer$53
- Novo Nordisk$32
- Novartis$26
- GSK$24
- plus $66 from 4 others
What the payments were for
- Travel & lodging$22647%
- Food & beverage$25453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $226 |
| AstraZeneca | 3 | $53 |
| Pfizer | 3 | $53 |
| Novo Nordisk | 2 | $32 |
| Novartis | 2 | $26 |
| GSK | 1 | $24 |
| Photocure Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$480 in reported general payments places this provider in the 90th percentile of 101 hospitalist providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 183 | $201,216 |
| JardianceEmpagliflozin | 178 | $186,438 |
| OzempicSemaglutide | 160 | $156,534 |
| MounjaroTirzepatide | 124 | $149,891 |
| EliquisApixaban | 143 | $109,899 |
| RybelsusSemaglutide | 71 | $93,787 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 18 | $71,297 |
| JanuviaSitagliptin Phosphate | 46 | $59,976 |
| XareltoRivaroxaban | 41 | $38,988 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $33,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,749 |
| LinzessLinaclotide | 25 | $30,444 |
| EntrestoSacubitril/Valsartan | 26 | $28,762 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $27,303 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 25 | $25,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $18 | $351,106307 claims |
| Novo NordiskOzempic, Rybelsus | $32 | $250,322231 claims |
| PfizerEliquis, Premarin | $53 | $112,814157 claims |
| MerckJanuvia | $12 | $59,97646 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $24 | $46,09170 claims |
| NovartisEntresto | $26 | $28,76226 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $25,12743 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $53 | $21,28359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 hospitalist providers in District of Columbia.
Other hospitalist in Washington
- Katherine GoodrichWashington$937K
- Sunil SaithWashington$213K
- Pedro Alcedo AndradeWashington$48K
- Jason GaloWashington$12K
- Roy TaoutelWashington$4K
- Jamar SlocumWashington$875
- Mehad MusbahWashington$617
- Kathryn HumesWashington$558
- Truptiben PatelWashington$412
- Mansour MehdiWashington$375
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.